Attached files
| file | filename |
|---|---|
| EX-23.3 - CONSENT OF WITHUMSMITH+BROWN, PC, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR FSD - Gemini Therapeutics, Inc. /DE | ea135565ex23-3_geminitherap.htm |
| EX-5.1 - OPINION OF GOODWIN PROCTER LLP. - Gemini Therapeutics, Inc. /DE | ea135565ex5-1_geminitherap.htm |
| S-1 - REGISTRATION STATEMENT - Gemini Therapeutics, Inc. /DE | ea135565-s1_geminitherap.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated October 30, 2020 with respect to the financial statements of Gemini Therapeutics, Inc. included in the Registration Statement (Form S-1) and related Prospectus of Gemini Therapeutics, Inc. (f/k/a FS Development Corp.) for the registration of 9,506,000 shares of its common stock.
| /s/ Ernst & Young LLP | |
| Boston, Massachusetts | |
| February 16, 2021 |